Autobytel to Present at Upcoming 2017 Investor Conferences
May 09, 2017 20:09 pm UTC| Business
IRVINE, Calif., May 09, 2017 -- Autobytel Inc. (NASDAQ:ABTL), a pioneer and leading provider of digital automotive services connecting in-market car buyers with dealers and OEMs, will present at four financial...
TESARO Announces First-Quarter 2017 Operating Results
May 09, 2017 20:09 pm UTC| Business
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in...
Autobytel to Present at Upcoming 2017 Investor Conferences
May 09, 2017 20:09 pm UTC| Business
IRVINE, Calif., May 09, 2017 -- Autobytel Inc. (NASDAQ:ABTL), a pioneer and leading provider of digital automotive services connecting in-market car buyers with dealers and OEMs, will present at four financial...
Autobytel to Present at Upcoming 2017 Investor Conferences
May 09, 2017 20:09 pm UTC| Business
IRVINE, Calif., May 09, 2017 -- Autobytel Inc. (NASDAQ:ABTL), a pioneer and leading provider of digital automotive services connecting in-market car buyers with dealers and OEMs, will present at four financial...
TESARO Announces First-Quarter 2017 Operating Results
May 09, 2017 20:09 pm UTC| Business
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in...
Zafgen Reports First Quarter 2017 Financial Results
May 09, 2017 20:08 pm UTC| Business
-ZGN-1061 Phase 1 Data Support Continued Development; On Track to Initiate Phase 2 Clinical Trial in Patients with Type 2 Diabetes in Second Half of This Year- BOSTON, May 09, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), today...
TESARO Announces First-Quarter 2017 Operating Results
May 09, 2017 20:08 pm UTC| Business
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in...